Loading organizations...
§ Private Profile · North Brunswick, NJ, USA
Biopharmaceutical company developing LFA-1 targeted therapeutics. Leukothera treats blood cancers, autoimmune diseases, & latent HIV.
Actinobac Biomed is a North Brunswick, New Jersey-based biopharmaceutical company developing therapeutics that target Leukocyte Function Antigen-1 to treat hematological malignancies, autoimmune diseases, and latent HIV infections. The firm's lead clinical candidate, Leukothera, utilizes a protein derived from oral bacteria to selectively eliminate disease-causing white blood cells in patients with relapsed leukemia and lymphoma. Operating with a single employee, the early-stage biotechnology enterprise has secured over $5 million in total funding, including a $3 million Phase II grant. This financial backing has been provided by key institutional partners such as Foundation Venture Capital Group and the National Institutes of Health. The organization leverages foundational scientific research originating from Rutgers University and has successfully obtained Orphan Drug Designation from the FDA for its primary oncology applications. Actinobac Biomed was founded in 2009 by Dr. Scott Kachlany.
Actinobac Biomed has raised $5.4M across 3 funding rounds.
Actinobac Biomed has raised $5.4M in total across 3 funding rounds.
Actinobac Biomed has raised $5.4M across 3 funding rounds. Most recently, it raised $4.4M Other Equity in July 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 14, 2017 | $4.4M Venture Round | Kairos Ventures | — | Announced |
| Oct 27, 2014 | $900K Grant | National Cancer Institute | — | Announced |
| Feb 23, 2013 | $100K Seed | Foundation Venture Capital Group | — | Announced |
Actinobac Biomed has raised $5.4M in total across 3 funding rounds.
Actinobac Biomed's investors include Kairos Ventures, National Cancer Institute, Foundation Venture Capital Group.